1

1 TITLE: Predicting thoracic aortic dissection in a diverse biobank using a 2 polygenic risk score

- 3
- Authors: John DePaolo, MD, PhD,¹* Siavash Zamirpour, MS,²* Sarah Abramowitz, 4
- BA,¹ Gina Biagetti, MD,³ Renae Judy, MS,¹ Cameron Beeche, BS,^{4,5} Jeffrey Duda⁶, 5
- James Gee⁶, Walter R. Witschey, PhD,⁶ Julio A. Chirinos, MD, PhD,⁵ Nicholas J. Goel, 6
- MD,⁷ Nimesh Desai, MD, PhD,⁷ Wilson Y. Szeto, MD,⁷ Dongchuan Guo, PhD,⁸ Dianna 7
- M. Milewicz, MD, PhD,⁸ Michael G. Levin, MD,^{5,9} James P. Pirruccello, MD^{2,10,11#} Scott M. Damrauer, MD,^{3,9,12,13#} 8
- 9
- 10

Affiliations: 11

- 12 ¹ Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 13
- ² Institute for Human Genetics, University of California San Francisco, San Francisco, 14
- 15 CA. USA.
- 16 ³ Division of Vascular Surgery and Endovascular Therapy, Department of Surgery,
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 17
- ⁴ Department of Bioengineering, University of Pennsylvania, PA, USA. 18
- 19 ⁵ Division of Cardiovascular Medicine, Department of Medicine, Perelman School of
- Medicine, University of Pennsylvania, PA, USA. 20
- ⁶ Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 21 22 PA, USA.
- ⁷ Division of Cardiovascular Surgery, Department of Surgery, Perelman School of 23
- Medicine, University of Pennsylvania, Philadelphia, PA, USA. 24
- ⁸ Division of Medical Genetics, Department of Internal Medicine, McGovern Medical 25
- School, University of Texas Health Science Center at Houston, Houston, TX, USA. 26
- ⁹ Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. 27
- ¹⁰ Division of Cardiology, University of California San Francisco, San Francisco, CA, 28 29 USA.
- ¹¹ Bakar Computation Health Sciences Institute, University of California San Francisco, 30 San Francisco, CA, USA. 31
- ¹² Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, 32
- PA. USA. 33
- ¹³ Department of Genetics, Perelman School of Medicine, University of Pennsylvania, 34
- 35 Philadelphia, PA, USA.
- 36
- 37
- 38 * These authors contributed equally to this work
- [#] These authors jointly supervised the work 39
- 40
- 41
- Brief Title: Polygenic scoring for dissection risk 42
- 43 **Word count** : 4305
- 44 References : 41
- 45 Tables :1
- Figures 46 :4

2

47

48 Address for correspondence:

- 49 Scott Damrauer, MD
- 50 Division of Vascular Surgery and Endovascular Therapy
- 51 Hospital of the University of Pennsylvania
- 52 3400 Civic Center Drive, 14th Floor South Perelman Center
- 53 Philadelphia, PA 19104
- 54 Office: 215-615-1698
- 55 <u>damrauer@upenn.edu</u>

3

56 Abstract

57 **Background**: Thoracic aortic dissection is a life-threatening condition that often occurs 58 in the presence of aortic dilation. Despite a known association between ascending aortic 59 diameter (AscAoD) and dissection risk, predicting dissection risk remains challenging. **Objectives**: Determine whether common variant genetics can be used to improve 60 61 identification of individuals most at risk for dissection. 62 **Methods:** A genome wide association study (GWAS)-by-subtraction was performed to 63 characterize the diameter-independent genetics of thoracic aortic dissection by subtracting a GWAS of aortic diameter (AoD) from a GWAS of thoracic aortic aneurysm 64 65 and dissection (TAAD). A polygenic risk score (PRS) was calculated using the PRS-Continuous Shrinkage statistical package and evaluated for its ability to predict aortic 66 67 dissection. The primary analytic cohort was Penn Medicine Biobank (PMBB) which 68 comprises volunteers consenting to linkage of health records with biospecimens, 69 including DNA which has undergone genome-wide genotyping; additional analyses 70 were performed in the National Institutes of Health All of Us (AoU) cohort. 71 Results: We identified 43 significant genetic risk loci in our GWAS-by-subtraction and 72 derived a "Dissection-PRS." In the PMBB, the Dissection-PRS associated with an 73 increased risk of prevalent dissection (odds ratio [OR]=2.13 per 1 standard deviation 74 [sd] increase in Dissection-PRS, 95% confidence interval [CI] 1.91 to 2.39, P<0.001), 75 These results were consistent when excluding individuals with pathogenic or likely 76 pathogenic variants in established aortopathy genes. When adjusting for clinical risk factors including ascending aortic diameter, the association of the Dissection-PRS with 77 78 prevalent dissection attenuated but remained significant (OR=1.62 per 1 sd increase in

- PRS, 95% CI 1.36 to 1.94, P<0.001). The addition of the PRS to a model containing
- 80 age, sex, clinical risk factors, and ascending aortic diameter substantially improved
- 81 model discrimination (base model area under the receiver operator characteristic curve
- 82 [AUROC]=0.676, 95% CI 0.651 to 0.702; with addition of PRS AUROC=0.723, 95% CI
- 83 0.702 to 0.744). Analysis in AoU demonstrated similar findings.
- 84 **Conclusions:** A common-variant PRS can predict aortic dissection in a diverse
- 85 population.

86 Abbreviations

- **AoD** Aortic diameter
- 88 AscAoD Ascending aortic diameter
- **AUROC** Area under the receiver operator characteristic curve
- **CI** Confidence interval
- **CT** Computed tomography
- **CRF** Clinical Risk Factors
- **DesAoD** Descending aortic diameter
- **PRS** Polygenic risk score
- **ROC** Receiver operator characteristic curve
- 96 SEM Structural equation modeling
- **TAAD** Thoracic aortic aneurysm and dissection
- **TTE** Transthoracic echocardiography

6

100 Main Text

101 Introduction

102 Thoracic aortic dissection is characterized by tearing of the intimal layer of the 103 thoracic aorta, more commonly in the ascending portion (Stanford Type A dissection), 104 leading to formation of a false lumen resulting in antegrade and/or retrograde 105 malperfusion.¹ Dissection has an incidence rate of approximately 3-10 per 100,000 individuals annually,²⁻⁵ and although rare, acute dissection can have devastating health 106 107 consequences with 30-day mortality rates ranging from 17% to more than 50% when considering out-of-hospital deaths.⁶⁻¹¹ Currently, individuals with dilated or aneurysmal 108 109 thoracic aortas are treated with aggressive blood pressure management and serial 110 imaging with elective surgical repair at ascending thoracic aortic diameters (AscAoD) \geq 5-5.5 cm.¹² However, it has become increasingly evident by the prevalence of dissection 111 112 among individuals with AscAoD < 5.5 cm that this size cutoff alone is insufficient to guide clinical decision making.¹³ 113

114 Dissection, along with ascending and descending thoracic aortic aneurysms, are 115 included in the group of related conditions referred to as thoracic aortic aneurysm and 116 dissection (TAAD). Rare pathogenic (P) or likely pathogenic (LP) variants in several 117 Mendelian aortopathy genes associated with hereditary TAAD (HTAAD) are causally linked to familial and/or syndromic disease.^{14,15} Notably, due to overwhelming genetic 118 119 risk, the size threshold for surgical intervention to prevent dissection is lower among 120 individuals with P/LP rare variants in a subset of aortopathy genes associated with familial or syndromic disease.¹² Despite TAAD being historically thought of as a 121 122 Mendelian disease, approximately 80% of cases of TAAD occur among individuals

7

123	without evidence of heritable disease. ¹⁶ Recent genome-wide association studies
124	(GWAS) have identified dozens of common single nucleotide variants (SNVs)
125	associated with increased thoracic aortic diameter (AoD), ^{17,18} and TAAD. ¹⁹ To
126	characterize common variant risk, polygenic risk scores (PRS) have been constructed
127	from these GWAS data using different methodologies and have shown consistent
128	association with prevalent and incident thoracic aortic disease in different biobank
129	cohorts. ¹⁷⁻¹⁹
130	In this study, we utilized Genomic-Structural Equation Modeling (Genomic-SEM)
131	to perform a GWAS-by-subtraction to determine the diameter independent common
132	genetic variants associated with dissection. This procedure revealed 43 genome-wide
133	significant genetic risk loci associated with diameter-independent thoracic aortic
134	disease. From this GWAS we generated a "Dissection-PRS" that better associates with
135	prevalent dissection compared to existing PRSs. Using this novel Dissection-PRS, we
136	were able to predict individuals who are most at risk of dissection independent of other
137	clinical factors, including aortic size.

138

139 Methods

140 Study Population

141 <u>PMBB</u>

The Penn Medicine BioBank is a genomic and precision medicine cohort
comprising participants who receive care in the Penn Medicine health system and who
consent to linkage of electronic health records with biospecimens, including 43,731 with
DNA which has undergone whole exome sequencing and 43,623 which has undergone

146	genome-wide genotyping (pmbb.med.upenn.edu). ²⁰ Among these individuals, 7,947
147	have had at least one transthoracic echocardiography (TTE) study with a recorded
148	measurement of AscAoD or a computed tomography (CT) scan with an interpretable
149	aortic diameter. Details of the genetic acquisition, quality control, and assignment of
150	population groups are included in the Supplemental Methods .
151	
152	All of Us
153	The All of Us (AOU) research program is a multi-site, prospective cohort study in
154	the United States. ²¹ The enrollment process included a physical examination and
155	biospecimen collection, with follow-up based on electronic health record (EHR) records
156	and surveys. All participants provided written, informed consent. Analysis of AOU was
157	considered exempt by the UCSF IRB (#22-37715). Further information regarding
158	genetic information and data analysis of the AOU cohort are provided in the
159	Supplemental Methods.
160	
161	Primary outcome in the PMBB
162	The primary outcome of our study was thoracic aortic dissection. Dissection was
163	defined either as ≥ 2 outpatient or ≥ 1 inpatient encounters coded with <i>International</i>
164	Classification of Diseases, 10 th Revision (ICD10) diagnosis codes I71.01 or I71.03, or
165	International Classification of Diseases, Ninth Revision (ICD9) codes 441.01 or 441.03.
166	
167	Clinical Covariate Selection

9

168	Previous studies have identified several clinical variables as risk factors for
169	ascending thoracic aortic dilation and/or dissection. ²²⁻²⁵ From these studies, we selected
170	those covariates that are most easily and universally assessed, referred to as clinical
171	risk factors (CRF), including height, weight, body mass index (BMI), body surface area
172	(BSA), systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate
173	(HR). For each individual, the mean value of each covariate taken over time was used
174	in the analysis. In a subset of the analyses, we also used AscAoD as measured by
175	either TTE, or computed tomography (CT). Participant TTE measurements were derived
176	from clinical echocardiography reports recorded in EHR. CT measurements were
177	derived using automated segmentation of the ascending aorta as previously
178	described. ²⁶
179	

180 Genome Wide Association Study

181 GWAS-by-subtraction was performed using Genomic-Structural Equation Modeling (SEM), as previously described.²⁷ Genomic-SEM is a flexible modeling 182 183 framework that allows a user to create systems of equations to model relationships 184 between the genetic components of observed traits and related latent traits. Because 185 TAAD comprises both aortic aneurysm (i.e. large aortic diameter) and dissection, we 186 posited that subtracting the genetic contribution of aortic size from TAAD would isolate 187 the genetics of aortic dissection. Using publicly available summary statistics from GWAS of TAAD,¹⁹ ascending aortic diameter (AscAoD),¹⁷ and descending aortic 188 diameter (DesAoD)¹⁷ (summary information in **Supplemental Table 1**) we employed 189 190 the genomic-SEM framework to perform GWAS-by-subtraction based on a Cholesky

10

191	decomposition model that subtracts out the genetic covariance contributed by multiple
192	related traits resulting in a novel GWAS of latent traits. ²⁸ This allowed us to identify
193	variants uniquely associated with TAAD and independent of AscAoD or DesAoD. ²⁹
194	The objective of this method was to estimate the association with TAAD
195	independent of that variant's association with AscAoD and DesAoD for each genetic
196	variant identified in the TAAD parent GWAS. To do this, the Cholesky decomposition
197	model (Supplemental Figure 1) regressed each genetic variant on three latent factors:
198	one defined as all aortic diameter plus TAAD (AscAoD + DesAoD + TAAD), a second
199	defined as descending aortic diameter + TAAD – ascending aortic diameter [(DesAoD +
200	TAAD) – AscAoD], and a third defined as diameter-independent TAAD (TAAD –
201	(AscAoD + DesAoD)), which we posit represents dissection alone. In creating such a
202	model, we assume that all genetic variants that affect thoracic aortic diameter also
203	affect TAAD. The analysis allows for three paths by which a genetic variant can affect
204	TAAD: first, mediated through aortic diameter + the TAAD latent trait (Latent Trait 1);
205	second, mediated through just the DesAoD + TAAD) – AscAoD latent trait (Latent Trait
206	2), and finally mediated through the diameter-independent TAAD latent trait (Latent Trait
207	3), our latent trait of focus. Each genetic variant was regressed on each latent trait to
208	determine the effect size specific to the latent trait of interest. Independent lead loci for
209	the diameter-independent TAAD latent trait were then selected using $P < 5 \times 10^{-8}$, a radius
210	of 250kb, and an LD threshold of $r^2 < 0.001$.

211

212 Polygenic risk score creation

11

PRS-CSx-auto³⁰ was used to construct a PRS for each of the following traits: 1)
AscAoD from a GWAS performed among 38,694 UKB participants;¹⁷ 2) TAAD from a
GWAS among a diverse population of 461,669 MVP participants (8,626 cases, 453,043
disease-free controls);¹⁹ 3) thoracic aortic dissection ("Dissection-PRS") using our
GWAS-by-subtraction summary statistics described above. These are described further
in the Supplemental Methods.

219 To apply each PRS in the PMBB, individual participant scores were calculated 220 using pgsc calc, a pipeline developed by the PGS Catalog that computes individual scores by combining imputed genotypes with PRS weights.³¹ As allele frequency 221 222 differences across diverse populations can influence PRS distribution and limit 223 accuracy, pgsc_calc allows a genetic principal component (PC)-based method to 224 normalize scores across populations by adjusting the mean and variance relative to the 1000 Genomes Project and Human Genomes Diversity Project (HGDP).³² In this 225 226 approach, a PC space is created using reference populations and a PRS is modeled as 227 a linear function of the PCs. Score residuals are calculated as the difference between 228 the observed and predicted PRS, and then divided by the standard deviation of the 229 residuals. This ensures that the adjusted PRS values have a mean of 0 when 230 considering the influence of population diversity. To adjust for the variations in PRS 231 range, the variance of the residuals is modeled as a function of the PCs, and then is 232 used to normalize the residual PRS. The variance of the final PRS values distribution is 233 therefore approximately 1 across all populations.

234

235 Prediction model creation

12

236	Using the selected clinical covariates and the Dissection-PRS we created, we
237	derived the following six regression models to predict dissection in the PMBB:
238	1) Age + Sex + genetic PC1-PC5 (Age + Sex model)
239	2) Age + Sex + genetic PC1-PC5 + Clinical Risk Factors (Age + Sex + CRF
240	model)
241	3) Age + Sex + genetic PC1-PC5 + Clinical Research Factors + Dissection-PRS
242	(Age + Sex + CRF + PRS model)
243	4) Age + Sex + genetic PC1-PC5 + Clinical Research Factors + AscAoD (Age +
244	Sex + CRF + AscAoD model)
245	5) Age + Sex + genetic PC1-PC5 + Clinical Research Factors + AscAoD +
246	Dissection-PRS (Age + Sex + CRF + AscAoD + PRS model)
247	Prediction model cross-validation and statistical testing is described in the
248	Supplemental Methods.
249	
250	Statistical Analysis
251	Multivariable logistic regression was employed to evaluate the risk of prevalent
252	dissection associated with the Dissection-PRS adjusting for age, sex, and genetic PCs
253	1-5. Incident dissection was modeled with Cox proportional hazards model with the R
254	survival package, ³³ and including the same covariates as above. Where described,
255	other covariates were added to specific analyses. All statistical analyses were performed
256	in R version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
257	Results

258 Study population for PRS Analysis

13

259	The primary analysis was performed in the Penn Medicine BioBank (PMBB).
260	There were 43,249 participants in the analytic cohort (Table 1), of which 262 individuals
261	had a diagnosis of aortic dissection. Of those with a dissection 86 (33%) were female,
262	76 (29%) were genetically similar to the 1000 Genomes Project (1000G) African
263	reference population (AFR), and the median age at analysis of individuals was 63.4
264	years (interquartile range [IQR]: 53.9-71.1 years). Among those without a diagnosis of
265	dissection, 21,576 (50%) were female, 11,035 (26%) were genetically similar to the
266	1000G AFR reference population, and the median age at analysis was 57.2 years (IQR:
267	42.5-67.2 years). Overall, individuals with a diagnosis of dissection had greater median
268	height (175.3 cm compared to 170.2 cm), weight (86.2 kg compared to 83.0 kg), body
269	mass index (BMI) [28.5 compared to 28.2], body surface area (BSA) [2.02 m ² compared
270	to 1.96 m ²], and systolic blood pressure (127.5 mmHg compared to 126.3 mmHg).
271	Concurrently, individuals with a diagnosis of dissection had a lower median diastolic
272	blood pressure (70.7 mmHg compared to 74.0 mmHg) and heart rate (73.9 beats per
273	minute [bpm] compared to 77.2 bpm).
274	Replication analyses were performed in the AOU cohort. There were 245,149
275	participants in this cohort, 133,444 of whom were genetically similar to the 1000G
276	European reference population (EUR) and 56,870 genetically similar to the 1000G AFR
277	reference population. Of the 205 individuals with diagnosis of dissection, 114 were
278	genetically similar to the 1000G EUR reference population and 65 were genetically
279	similar to the 1000G AFR reference population.

280

281 Genome-wide association study-by-subtraction

14

282	Previously, we published a GWAS of TAAD performed among a diverse
283	population in the Million Veterans Program (MVP) that identified 21 genetic risk loci
284	associated with TAAD. ¹⁹ Similarly, we published a GWAS of AscAoD and DesAoD in
285	the UK Biobank that identified 82 (AscAoD) and 47 (DesAoD) independent loci,
286	respectively. ¹⁷ In an attempt to better characterize the pathologic variants associated
287	with dissection but independent from thoracic AoD, we performed a GWAS-by-
288	subtraction ²⁷ using the Genomic-SEM framework ²⁹ to model the genetics of a novel
289	latent trait referred to as "diameter-independent dissection". Using this methodology, we
290	identified 43 independent risk loci that reached genome-wide significance and were
291	primarily associated with thoracic aortic dissection independently of their effects on
292	aortic diameter, (Figure 1, Supplemental Tables 2-3, Supplemental Figures 2-5)
293	described further in the Supplemental Results .
294	
295	Polygenic risk score association with prevalent thoracic aortic dissection
296	To determine whether we could use genetic information to better predict
297	dissection, we used our GWAS-by-subtraction summary statistics to create a diameter-
298	independent dissection PRS, referred to as the "Dissection-PRS." Individuals in the
299	PMBB, an independent cohort of patients separate from the parent GWAS included in
300	the GWAS-by-subtraction, were then used to assess the PRS association with prevalent
301	thoracic aortic dissection (Central Illustration).
302	Compared to individuals without a diagnosis of dissection (median PRS = 0.03 ,

303 95% CI = 0.01 to 0.04), individuals with a diagnosis of dissection had a significantly

304 higher median PRS (0.88, 95% CI 0.68 to 1.06, P=1.07x10⁻³⁰) [**Supplemental Figure**

305	6]. To further characterize the strength of the Dissection-PRS, we compared its
306	association with prevalent dissection in the PMBB to the association of either a TAAD-
307	PRS or AscAoD-PRS. Compared to the AscAoD-PRS (OR=1.27 per 1 sd increase in
308	PRS, 95% CI 1.13 to 1.44, P<0.001) and the TAAD-PRS (OR=1.34 per 1 sd increase in
309	PRS, 95% CI 1.19 to 1.51, P<0.001), the Dissection-PRS had a profoundly stronger
310	association with prevalent dissection (OR=2.13 per 1 sd increase in PRS, 95% CI 1.91
311	to 2.39, P<0.001) [Central Illustration]. This was consistent when individuals were
312	stratified by genetically similar population group (EUR: OR=1.93 per 1 sd increase in
313	PRS, 95% CI 1.67 to 2.23, P<0.001; AFR: OR=2.61 per 1 sd increase in PRS, 95% CI
314	2.14 to 3.18, P<0.001; Meta: OR=2.14 per 1 sd increase in PRS, 95% CI 1.91 to 2.41,
315	P<0.001) [Supplemental Figure 7], and when individuals carrying pathogenic/likely
316	pathogenic (P/LP) HTAAD gene variants were excluded from the analysis (OR=2.15 per
317	1 sd increase in PRS, 95% CI 1.91 to 2.42, <i>P</i> <0.001) [Supplemental Figure 8].
318	To validate our findings, analyses were replicated in the AOU cohort with genetic
319	data (N=245,149, including 132 participants with prevalent dissection). In this cohort,
320	the Dissection-PRS remained robustly associated with prevalent dissection (OR=1.48,
321	95% CI 1.27 to 1.74, P<0.001). When stratified by population group, similar results were
322	observed in the EUR population that included 73 cases of prevalent dissection
323	(OR=1.89, 95% CI 1.52 to 2.34, P<0.001), however the association was not statistically
324	significant among AFR population that included 38 cases of dissection (OR=1.09, 95%
325	CI 0.82 to 1.45, P=0.57). We conclude that the Dissection-PRS strongly associates with
326	prevalent dissection in PMBB across diverse populations, has been externally validated

16

in AOU though with an attenuated effect in the AFR population, and is independent of

328 P/LP HTAAD gene variants.

329 Effect of Dissection-PRS when adjusting for known risk factors

330 To determine if the Dissection-PRS was independently associated with prevalent

331 dissection independent of other risk factors, we performed multivariable logistic

regression analysis adjusting for CRF including age, sex, height, weight, BMI, BSA,

333 SBP, DBP, and HR. When we adjusted for these variables, the effect of the Dissection-

PRS remained consistent (OR=2.29 per 1 sd increase in PRS, 95% CI 1.97 to 2.65,

335 *P*<0.001) [**Figure 3**].

336 As AscAoD is the most critical clinical factor in determining when to offer surgical

intervention,^{12,13} we repeated our multivariable logistic regression to also adjust for

AscAoD among 7,974 individuals with AscAoD measured by TTE (7,414) or CT (560)

339 [Supplemental Table 4]. When adjusting for AscAoD alone (OR=1.59 per 1 sd increase

340 in PRS, 95% CI 1.33 to 1.92, *P*<0.001), or AscAoD and CRF (OR=1.61 per 1 sd

increase in PRS, 95% CI 1.35 to 1.92, P<0.001), the effect estimate of the Dissection-

342 PRS was attenuated but remained statistically significant [Figure 3]. These results

343 suggest that the risk of dissection associated with the Dissection-PRS is completely

independent of CRFs and largely independent of measured AscAoD.

345

346 PRS effect on predictive model calibration

To determine if the Dissection-PRS could improve identification of individuals at increased risk of dissection, we integrated the Dissection-PRS in prediction models and compared model performance with and without the PRS. To determine the effect of the

350	Dissection-PRS on model calibration, we assessed differences in model log-loss. Log-
351	loss is a measure of how close a predictive probability is to the corresponding actual
352	value with a lower log-loss equating to model improvement; a lower log-loss connotes
353	improved model calibration. A prediction model constructed with just age, sex, and the
354	first 5 genetic PCs (Age + Sex) had a log-loss of 0.075 (95% CI 0.070 to 0.080)
355	[Supplemental Figure 9]. Compared to an Age + Sex + CRF model that integrated
356	weight, BMI, height, BSA, SBP, DBP, and HR (log-loss=0.074, 95% CI 0.069 to 0.079),
357	an Age + Sex + CRF + Dissection-PRS had an improved model log-loss (log-
358	loss=0.071, 95% CI 0.066 to 0.076). Similarly, compared to an Age + Sex + CRF +
359	AscAoD model (log-loss=0.071, 95% CI 0.066 to 0.076), an Age + Sex + CRF +
360	AscAoD + Dissection-PRS had an improved log-loss (log-loss=0.069, 95% CI 0.064 to
361	0.074). To determine if the addition of the Dissection-PRS meaningfully improved model
362	calibration, we employed cross-model Bayesian ANOVA analysis of log-loss. The
363	addition of the Dissection-PRS to the Age + Sex + CRF model (mean log-loss difference
364	= -0.002, 95% credible interval -0.004 to 0.000; >95% probability of a practical
365	improvement in log-loss) and the Age + Sex + CRF + AscAoD (mean log-loss difference
366	= -0.002, 95% credible interval -0.004 to 0.001; >88% probability of a practical
367	improvement in log-loss) [Supplemental Figure 10, Supplemental Table 5],
368	demonstrated that the Dissection-PRS meaningfully improved model log-loss. These
369	results were also supported in analyses using a frequentist approach employing the
370	likelihood-ratio test (Supplemental Table 6). Finally, model calibration improvement
371	with the addition of the Dissection-PRS was consistent when stratifying by either sex
372	(Supplemental Figures 11-13, Summary Tables 7-8) or genetically similar population

18

373 group (**Supplemental Figures 14-16, Summary Tables 9-10**). These results lead us to

374 conclude that the Dissection-PRS consistently enhances clinical model calibration.

375 PRS effect on model discrimination

376 The ability to determine patients most at risk of dissection, especially among 377 individuals with ascending thoracic aortic dilation, remains elusive. To investigate 378 whether the Dissection-PRS could meaningfully improve clinical prediction model 379 discrimination between individuals with and without dissection, we tested whether its 380 inclusion increased model area under receiver operator characteristic curve (AUROC). 381 The Age + Sex model had an AUROC=0.572 (95% CI 0.547 to 0.597) [Figure 4]. The 382 Age + Sex + CRF model had an AUROC=0.634 (95% CI 0.610 to 0.657), whereas the 383 Age + Sex + CRF + Dissection-PRS had an AUROC=0.700 (95% CI 0.677 to 0.722). 384 Similarly, the Age + Sex + CRF + AscAoD model had an AUROC=0.676 (95% CI 0.651 385 to 0.702), whereas the Age + Sex + CRF + AscAoD + Dissection-PRS model had an AUROC=0.723 (95% CI 0.702 to 0.744). To determine if the addition of the PRS 386 387 meaningfully improved model discrimination, we once more employed cross-model 388 Bayesian analysis of AUROC. The addition of the Dissection-PRS to the Age + Sex + CRF model (AUROC mean difference = 0.066, 95% credible interval 0.057 to 0.075; 389 390 >95% probability of a practical improvement in AUROC) and the Age + Sex + CRF + 391 AscAoD (AUROC mean difference = 0.047, 95% credible interval 0.037 to 0.056; >95% 392 probability of a practical improvement in AUROC) [Supplemental Figure 17, 393 Supplemental Table 11, demonstrated that the Dissection-PRS meaningfully improved 394 model AUROC. These results were supported with frequentist analysis of differences in 395 AUROC using the DeLong method (Supplemental Table 12). Models were once more

19

396	compared when stratifying the cohort by either sex (Supplemental Figures 18-20,
397	Supplemental Tables 13-14) or genetically similar population group (Supplemental
398	Figure 21-23, Supplemental Tables 15-16) with consistent results. These results lead
399	us to conclude that the Dissection-PRS consistently enhances clinical model
400	discrimination.
401	Incident thoracic aortic dissection analysis
402	As a sensitivity analysis we performed time-to-event analyses using a Cox
403	proportional hazard model among individuals with incident dissection in the PMBB and
404	AOU. In the PMBB, for every 1 sd increase in Dissection-PRS, the hazard ratio (HR)
405	was 2.30 (95% CI 1.99 to 2.64, <i>P</i> <0.001) and 2.27 when adjusting for CRF (95% CI
406	1.96 to 2.62, P<0.001) [Supplemental Figure 24A]. When this analysis was restricted
407	to individuals with measured AscAoD prior to dissection, and AscAoD was adjusted for
408	with or without CRF, the effect of the Dissection-PRS remained significant (adjusted for
409	AscAoD: HR=1.65, 95% CI 1.08 to 2.53, P=0.021; adjusted for AscAoD + CRF:
410	HR=1.74, 95% CI 1.12 to 2.70, <i>P</i> =0.013) [Supplemental Figure 24B]. These incident
411	analysis results were consistent among individuals in the AOU validation cohort where a
412	1 sd increase in Dissection-PRS yielded an HR of 1.36 (95% CI 1.10 to 1.67, P=0.005).
413	Taken together, these results demonstrate that the Dissection-PRS is associated with
414	incident thoracic aortic dissection across two diverse cohorts.
415	

416 **Discussion**

417 Identification of diameter-independent risk factors for dissection remains one of418 the key unresolved challenges in preventing premature deaths due to thoracic aortic

20

disease. In this study, we performed a GWAS-by-subtraction that identified 43 genetic
loci associated with diameter-independent thoracic aortic disease, 20 of which were
previously unreported. From our summary statistics, we created a PRS that strongly
associated with dissection in the PMBB independent of clinical variables including
AscAoD and validated our findings in AOU. We then demonstrated that inclusion of the
Dissection-PRS in a clinical risk prediction model improves model calibration and
discrimination across diverse populations.

426 The explanation for the improvement in the strength of association with prevalent 427 and incident dissection provided by the Dissection-PRS, as compared to the TAAD-PRS 428 or AscAoD-PRS, is likely partially explained by the identification of novel variants 429 associated with dissection using the GWAS-by-subtraction methodology. However, 430 some of the improvement is also likely due to the subtle statistical reweighting of known 431 variants such that the weights are substantially changed and reflected in the overall 432 observed PRS effect. For example, the effect estimate of the CDH13 risk locus in the 433 TAAD GWAS was -0.12 while the effect estimate in our GWAS-by-subtraction was -434 0.14. The enhancement in PRS performance raises the prospect of a true dissection 435 GWAS, rather than the present one inferred through latent values, and whether a PRS 436 from such a GWAS would exceed what we have shown in this present study. In future 437 work, it will also be interesting to attempt to de-convolve the Dissection-PRS into 438 recognizable features (e.g., features of aortic geometry; properties of the aortic wall; 439 etc.).

440 Determining which patients should receive prophylactic surgical intervention to 441 prevent an acute dissection, and the timing of that intervention, represents an ongoing

21

442 challenge in cardiovascular medicine and surgery. While the standard AscAoD size threshold for repair remains 5-5.5 cm.¹² it is clear from retrospective data that this 443 threshold is insufficient to identify at-risk individuals.¹³ Despite myriad attempts to 444 develop algorithms to better predict dissection risk,³⁴⁻³⁷ there remains limited clinical 445 446 implementation of risk factors other than AscAoD, rate of diameter growth, and family 447 history. Genetic data is changing the way we interpret multi-factorial disease risk. Our 448 results suggest that using common genetic risk factors aggregated in a PRS can 449 contribute to improved assessment of dissection risk and may enhance patient selection 450 for surgical intervention.

451 Importantly, the Dissection-PRS had a similar effect on dissection risk across 452 diverse populations. This was true in incident analyses across both the primary and 453 validation cohorts, as well as prevalent analyses in the primary cohort. We also 454 observed robust prediction model discrimination improvement with the addition of the 455 Dissection-PRS in both the EUR and AFR population groups. Extensive investigation has been performed on the lack of portability of PRS across diverse populations.^{38,39} 456 457 The present multi-trait GWAS-by-subtraction is benefited by the diversity inherent in the previously published TAAD GWAS in the MVP and not penalized by subtracting out 458 459 AoD using summary statistics from a GWAS largely performed in an EUR population. 460 The use of multi-trait GWAS from more diverse parent GWAS data to derive equitable 461 PRS may improve PRS portability as biobanks continue to work to overcome historical 462 lack of diversity.

463 Determining if a prediction model that includes a PRS improves patient
 464 identification will require prospective investigation. For example, future studies may

22

465 benefit from incorporating a model that includes a PRS for thoracic aortic dissection 466 among patients at risk of dissection to identify those patients who could be considered for expedited repair at a lower diameter threshold. One way to address this is to 467 468 prospectively enroll individuals at high volume aortic centers with dilated ascending 469 thoracic aortas to have genetic testing and PRS calculation, and integrating the 470 individual PRS into a model to predict dissection risk. Subsequently, individuals would 471 be followed over time to determine the utility of such a model. As thoracic aortic 472 dissection is a relatively rare event, coordinated efforts across many different aortic 473 centers may be better powered to demonstrate an effect.

474 Limitations

475 This study has several limitations. First, our GWAS-by-subtraction is not a true 476 GWAS of dissection and should not be misconstrued as serving that purpose, although 477 it will be interesting to compare these findings with future thoracic dissection GWAS as 478 they become available. Second, the PMBB is enriched for cases of dissection and the 479 robust association of the Dissection-PRS with prevalent and incident dissection may be 480 overestimated in this cohort. Third, dissection is a relatively rare event and therefore 481 any understanding of the true predictive capacity of the Dissection-PRS would be best 482 evaluated prospectively. Fourth, for the TTE data in the PMBB, each TTE was 483 interpreted by a cardiologist in a clinical echocardiography lab, which is accredited by 484 the Intersocietal Commission for the Accreditation of Echocardiography Labs and 485 staffed by cardiologists who are board-certified in echocardiography. However, each 486 TTE was not interpreted by the same cardiologist and small differences in measurement 487 and interpretation may exist between studies. Additionally, although we used the largest

488	and most diverse GWAS studies available to perform our GWAS-by-subtraction, the
489	AscAoD and DesAoD GWAS were performed in the UKB which is almost entirely
490	composed of individuals genetically similar to the 1000G EUR reference population.
491	Conclusions
492	Our findings suggest that our GWAS-by-subtraction allowed the construction of a
493	Dissection-PRS that associates with prevalent dissection. Using this PRS, we can better
494	predict individuals at increased risk of acute dissection. Future clinical implementation of
495	our model requires prospective studies to investigate the benefit of identifying patients
496	at increased risk of dissection and offering earlier surgical intervention.
497	
498	
499	Data Availability
500	The summary statistics for the GWAS-by-subtraction will be made publicly
501	available on Zenodo. The PRS weights will be submitted to the Polygenic Score
502	Catalog. All other data may be made available upon reasonable request to the
503	corresponding author.
504	
505	Acknowledgements
506	We acknowledge Perline Demange, PhD, Andrew D. Grotzinger, PhD, Michael
507	G. Nivard, PhD, and Elliot M. Tucker-Drob, PhD who assisted in the methodology of
508	GWAS-by-subtraction and maintain the Genomic Structural Equation Modeling package
509	in R. We acknowledge the Penn Medicine BioBank (PMBB) for providing data and
510	thank the patient-participants of Penn Medicine who consented to participate in this

24

511 research program. We would also like to thank the Penn Medicine BioBank team and 512 Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is 513 approved under IRB protocol# 813913 and supported by Perelman School of Medicine 514 at University of Pennsylvania, a gift from the Smilow family, and the National Center for 515 Advancing Translational Sciences of the National Institutes of Health under CTSA 516 award number UL1TR001878. The summary statistics for the TAAD GWAS performed 517 in the MVP were obtained through dbGaP, accession number phs001672.v11.p1. The 518 authors thank the MVP staff, researchers, and volunteers who have contributed to MVP, 519 and especially participants who previously served their country in the military and now 520 generously agreed to enroll in the study. (See https://www.research.va.gov/mvp/ for 521 more details). This research is based on data from the Million Veteran Program, Office 522 of Research and Development, Veterans Health Administration, and was supported by 523 the Veterans Administration (VA) MVP award #000. The All of Us Research Program is 524 supported by the National Institutes of Health, Office of the Director: Regional Medical 525 Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 526 OD026551: 1 OT2 OD026555: IAA #: AOD 16037: Federally Qualified Health Centers: 527 528 HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 529 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems 530 Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 531 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 532 OD025337; 1 OT2 OD025276. We gratefully acknowledge All of Us participants for their 533 contributions, without whom this research would not have been possible. We also thank

25

- the National Institutes of Health's <u>All of Us Research Program</u> for making available the
 participant data examined in this study.
- 536

537 Sources of Funding

- 538 J.D. is supported by the American Heart Association (23POST1011251). The
- 539 views expressed in this article are those of the authors and do not necessarily reflect
- 540 the position or policy of the Department of Veterans Affairs or the United States
- 541 government. W.R.W. is supported by NIH R01 HL171709, P41 EB029460, and R01
- 542 HL169378. D.M.M. and D.C.G. are supported by the NIH (R01HL109942), the John
- 543 Ritter Foundation. M.G.L. received support from the Doris Duke Foundation (2023-
- 544 0224) and Department of Veterans Affairs Biomedical Research and Development

545 Award IK2-BX006551. J.P.P is supported by the NIH (K08HL159346).

546

547 Disclosures

M.G.L. receives research support to his institution from MyOme outside of this work. S.M.D receives research support to his institution from RenalytixAI and in kind support from Novo Nordisk, both outside of this work. SMD is named as a co-inventor on a government-owned US Patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with Federal regulatory requirements.

- 555 Supplemental Material
- 556 Supplement 1

- 557 Supplemental table 1-2
- 558 Supplement 2
- 559 Supplemental Methods
- 560 Supplemental Results
- 561 Supplemental Authors
- 562 Supplemental Tables 3-16
- 563 Supplemental Figures 1-24

27

564 **References**

- 565 1. Gudbjartsson T, Ahlsson A, Geirsson A, Gunn J, Hjortdal V, Jeppsson A,
- 566 Mennander A, Zindovic I, Olsson C. Acute type A aortic dissection a review.
- 567 Scandinavian Cardiovascular Journal. 2020;54:1-13. doi:
- 568 10.1080/14017431.2019.1660401
- 569 2. DeMartino RR, Sen I, Huang Y, Bower TC, Oderich GS, Pochettino A, Greason
- 570 K, Kalra M, Johnstone J, Shuja F, et al. Population-Based Assessment of the
- 571 Incidence of Aortic Dissection, Intramural Hematoma, and Penetrating Ulcer, and
- 572 Its Associated Mortality From 1995 to 2015. *Circ Cardiovasc Qual Outcomes*.
- 573 2018;11:e004689. doi: 10.1161/CIRCOUTCOMES.118.004689
- 3. Clouse WD, Hallett JW, Jr., Schaff HV, Spittell PC, Rowland CM, Ilstrup DM,
- 575 Melton LJ, 3rd. Acute aortic dissection: population-based incidence compared
- 576 with degenerative aortic aneurysm rupture. *Mayo Clin Proc.* 2004;79:176-180.

577 doi: 10.4065/79.2.176

- 578 4. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm
- 579 and dissection: increasing prevalence and improved outcomes reported in a
- 580 nationwide population-based study of more than 14,000 cases from 1987 to
- 581 2002. *Circulation*. 2006;114:2611-2618. doi: 10.1161/circulationaha.106.630400
- 582 5. Mody PS, Wang Y, Geirsson A, Kim N, Desai MM, Gupta A, Dodson JA,
- 583 Krumholz HM. Trends in aortic dissection hospitalizations, interventions, and
- 584 outcomes among medicare beneficiaries in the United States, 2000-2011. *Circ*
- 585 Cardiovasc Qual Outcomes. 2014;7:920-928. doi:
- 586 10.1161/circoutcomes.114.001140

587	6.	Pape Linda A, Awais M, Woznicki Elise M, Suzuki T, Trimarchi S, Evangelista A,
-----	----	--

- 588 Myrmel T, Larsen M, Harris Kevin M, Greason K, et al. Presentation, Diagnosis,
- and Outcomes of Acute Aortic Dissection. Journal of the American College of
- 590 *Cardiology*. 2015;66:350-358. doi: 10.1016/j.jacc.2015.05.029
- 591 7. McClure RS, Ouzounian M, Boodhwani M, El-Hamamsy I, Chu MWA, Pozeg Z,
- 592 Dagenais F, Sikdar KC, Appoo JJ. Cause of Death Following Surgery for Acute
- 593 Type A Dissection: Evidence from the Canadian Thoracic Aortic Collaborative.

594 Aorta (Stamford). 2017;5:33-41. doi: 10.12945/j.aorta.2017.16.034

- 595 8. Verstraeten A, Luyckx I, Loeys B. Aetiology and management of hereditary
- 596 aortopathy. Nat Rev Cardiol. 2017;14:197-208. doi: 10.1038/nrcardio.2016.211
- 597 9. Melvinsdottir IH, Lund SH, Agnarsson BA, Sigvaldason K, Gudbjartsson T,
- 598 Geirsson A. The incidence and mortality of acute thoracic aortic dissection:
- results from a whole nation study. *Eur J Cardiothorac Surg.* 2016;50:1111-1117.
- 600 doi: 10.1093/ejcts/ezw235
- 10. Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM, Oxford
- 602 Vascular S. Population-based study of incidence and outcome of acute aortic
- dissection and premorbid risk factor control: 10-year results from the Oxford
- 604 Vascular Study. *Circulation*. 2013;127:2031-2037. doi:
- 605 10.1161/CIRCULATIONAHA.112.000483
- 11. Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem
- 607 U, Ehrlich MP, Trimarchi S, Braverman AC, Myrmel T, et al. Insights From the
- 608 International Registry of Acute Aortic Dissection: A 20-Year Experience of

29

609 Collaborative Clinical Research. *Circulation*. 2018;137:1846-1860. doi:

- 610 10.1161/CIRCULATIONAHA.117.031264
- 12. Isselbacher EM, Preventza O, Hamilton Black J, 3rd, Augoustides JG, Beck AW,
- Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, et al.
- 613 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease:
- 614 A Report of the American Heart Association/American College of Cardiology
- 515 Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146:e334-
- 616 e482. doi: 10.1161/CIR.00000000001106
- 13. Pape LA, Tsai TT, Isselbacher EM, Oh JK, O'Gara P T, Evangelista A, Fattori R,
- 618 Meinhardt G, Trimarchi S, Bossone E, et al. Aortic diameter >or = 5.5 cm is not a
- 619 good predictor of type A aortic dissection: observations from the International
- 620 Registry of Acute Aortic Dissection (IRAD). *Circulation*. 2007;116:1120-1127. doi:
- 621 10.1161/circulationaha.107.702720
- 622 14. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, McNamara J,
- 623 Driscoll A, Wu X, Schmidt EM, et al. Clinical Implications of Identifying
- 624 Pathogenic Variants in Individuals With Thoracic Aortic Dissection. Circ Genom
- 625 *Precis Med.* 2019;12:e002476. doi: 10.1161/CIRCGEN.118.002476
- 15. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Ades LC, Andelfinger GU,
- 627 Arnaud P, Boileau C, Callewaert BL, et al. Clinical Validity of Genes for Heritable
- 628 Thoracic Aortic Aneurysm and Dissection. *J Am Coll Cardiol*. 2018;72:605-615.
- 629 doi: 10.1016/j.jacc.2018.04.089
- 630 16. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic
- 631 Diseases. *Circ Res.* 2019;124:588-606. doi: 10.1161/CIRCRESAHA.118.312436

632	17.	Pirruccello JP, Chaffin MD, Chou EL, Fleming SJ, Lin H, Nekoui M, Khurshid S,
633		Friedman SF, Bick AG, Arduini A, et al. Deep learning enables genetic analysis
634		of the human thoracic aorta. Nat Genet. 2022;54:40-51. doi: 10.1038/s41588-
635		021-00962-4
636	18.	Tcheandjieu C, Xiao K, Tejeda H, Lynch JA, Ruotsalainen S, Bellomo T, Palnati
637		M, Judy R, Klarin D, Kember RL, et al. High heritability of ascending aortic
638		diameter and trans-ancestry prediction of thoracic aortic disease. Nat Genet.
639		2022;54:772-782. doi: 10.1038/s41588-022-01070-7
640	19.	Klarin D, Devineni P, Sendamarai AK, Angueira AR, Graham SE, Shen YH,
641		Levin MG, Pirruccello JP, Surakka I, Karnam PR, et al. Genome-wide association
642		study of thoracic aortic aneurysm and dissection in the Million Veteran Program.
643		Nat Genet. 2023;55:1106-1115. doi: 10.1038/s41588-023-01420-z
644	20.	Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, Sirugo G,
645		Kember RL, Drivas TG, Dudek SM, et al. The Penn Medicine BioBank: Towards
646		a Genomics-Enabled Learning Healthcare System to Accelerate Precision
647		Medicine in a Diverse Population. Journal of Personalized Medicine.
648		2022;12:1974.
649	21.	Denny JC, Devaney SA, Gebo KA. The "All of Us" Research Program. Reply. N
650		Engl J Med. 2019;381:1884-1885. doi: 10.1056/NEJMc1912496
651	22.	Zhou Z, Cecchi AC, Prakash SK, Milewicz DM. Risk Factors for Thoracic Aortic

652 Dissection. *Genes (Basel)*. 2022;13. doi: 10.3390/genes13101814

- 23. Takada M, Yamagishi K, Tamakoshi A, Iso H, Group JS. Body Mass Index and
- 654 Mortality From Aortic Aneurysm and Dissection. *J Atheroscler Thromb*.
- 655 2021;28:338-348. doi: 10.5551/jat.57232
- 24. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, Mansour AM,
- Bin Mahmood SU, Ma WG, Brownstein AJ, et al. Height alone, rather than body
- 658 surface area, suffices for risk estimation in ascending aortic aneurysm. *J Thorac*
- 659 *Cardiovasc Surg.* 2018;155:1938-1950. doi: 10.1016/j.jtcvs.2017.10.140
- 660 25. Pirruccello JP, Lin H, Khurshid S, Nekoui M, Weng LC, Vasan RS, Isselbacher
- 661 EM, Benjamin EJ, Lubitz SA, Lindsay ME, Ellinor PT. Development of a
- 662 Prediction Model for Ascending Aortic Diameter Among Asymptomatic
- 663 Individuals. JAMA. 2022;328:1935-1944. doi: 10.1001/jama.2022.19701
- 664 26. Beeche C, Dib MJ, Zhao B, Azzo JD, Maynard H, Duda J, Gee J, Salman O,
- 665 Penn Medicine B, Witschey WR, Chirinos JA. Three-dimensional aortic
- geometry: clinical correlates, prognostic value and genetic architecture. *bioRxiv*.
- 667 2024. doi: 10.1101/2024.05.09.593413
- 668 27. Demange PA, Malanchini M, Mallard TT, Biroli P, Cox SR, Grotzinger AD,
- Tucker-Drob EM, Abdellaoui A, Arseneault L, van Bergen E, et al. Investigating
- 670 the genetic architecture of noncognitive skills using GWAS-by-subtraction. *Nat*
- 671 *Genet.* 2021;53:35-44. doi: 10.1038/s41588-020-00754-2
- 672 28. St Pourcain B, Eaves LJ, Ring SM, Fisher SE, Medland S, Evans DM, Davey
- 673 Smith G. Developmental Changes Within the Genetic Architecture of Social
- 674 Communication Behavior: A Multivariate Study of Genetic Variance in Unrelated

- 675 Individuals. *Biol Psychiatry*. 2018;83:598-606. doi:
- 676 10.1016/j.biopsych.2017.09.020
- 677 29. Grotzinger AD, Rhemtulla M, de Vlaming R, Ritchie SJ, Mallard TT, Hill WD, Ip
- 678 HF, Marioni RE, McIntosh AM, Deary IJ, et al. Genomic structural equation
- 679 modelling provides insights into the multivariate genetic architecture of complex
- 680 traits. Nat Hum Behav. 2019;3:513-525. doi: 10.1038/s41562-019-0566-x
- 30. Ruan Y, Lin YF, Feng YA, Chen CY, Lam M, Guo Z, Stanley Global Asia I, He L,
- 682 Sawa A, Martin AR, et al. Improving polygenic prediction in ancestrally diverse
- 683 populations. *Nat Genet*. 2022;54:573-580. doi: 10.1038/s41588-022-01054-7
- 31. Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, McMahon A, Abraham
- 685 G, Chapman M, Parkinson H, et al. The Polygenic Score Catalog as an open
- database for reproducibility and systematic evaluation. *Nature Genetics*.
- 687 2021;53:420-425. doi: 10.1038/s41588-021-00783-5
- 32. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample
- 689 Resource (IGSR) collection of open human genomic variation resources. *Nucleic*
- 690 Acids Res. 2020;48:D941-D947. doi: 10.1093/nar/gkz836
- 691 33. Therneau TM, Grambsch PM. The Cox Model. In: Therneau TM, Grambsch PM,
- eds. *Modeling Survival Data: Extending the Cox Model*. New York, NY: Springer
 New York; 2000:39-77.
- 694 34. von Kodolitsch Y, Schwartz AG, Nienaber CA. Clinical prediction of acute aortic
- 695 dissection. Arch Intern Med. 2000;160:2977-2982. doi:
- 696 10.1001/archinte.160.19.2977

- 697 35. Adriaans BP, Wildberger JE, Westenberg JJM, Lamb HJ, Schalla S. Predictive
- 698 imaging for thoracic aortic dissection and rupture: moving beyond diameters. *Eur*
- 699 *Radiol.* 2019;29:6396-6404. doi: 10.1007/s00330-019-06320-7
- 700 36. Heuts S, Adriaans BP, Rylski B, Mihl C, Bekkers S, Olsthoorn JR, Natour E,
- 701 Bouman H, Berezowski M, Kosiorowska K, et al. Evaluating the diagnostic
- 702 accuracy of maximal aortic diameter, length and volume for prediction of aortic
- 703 dissection. *Heart*. 2020;106:892-897. doi: 10.1136/heartjnl-2019-316251
- 37. Wu J, Qiu J, Xie E, Jiang W, Zhao R, Qiu J, Zafar MA, Huang Y, Yu C. Predicting
- in-hospital rupture of type A aortic dissection using Random Forest. *J Thorac Dis.*
- 706 2019;11:4634-4646. doi: 10.21037/jtd.2019.10.82
- 707 38. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*.
- 708 2016;538:161-164. doi: 10.1038/538161a
- 39. Ding Y, Hou K, Xu Z, Pimplaskar A, Petter E, Boulier K, Prive F, Vilhjalmsson BJ,
- 710 Olde Loohuis LM, Pasaniuc B. Polygenic scoring accuracy varies across the
- 711 genetic ancestry continuum. *Nature*. 2023;618:774-781. doi: 10.1038/s41586-
- 712 023-06079-4
- 713 40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
- Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome
- association and population-based linkage analyses. *Am J Hum Genet*.
- 716 2007;81:559-575. doi: 10.1086/519795
- 717 41. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin
- 718 RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of

719	genetic variation from	1,092 human genomes.	<i>Nature</i> . 2012;491:56-65. doi:
/ 1/	genere	.,	

- 720 10.1038/nature11632
- 42. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M,
- Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide
- association scan results. *Bioinformatics*. 2010;26:2336-2337. doi:
- 724 10.1093/bioinformatics/btq419
- 43. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan
- 726 MT, Carey VJ. Software for computing and annotating genomic ranges. *PLoS*
- 727 *Comput Biol.* 2013;9:e1003118. doi: 10.1371/journal.pcbi.1003118
- 44. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set
- analysis of GWAS data. *PLoS Comput Biol.* 2015;11:e1004219. doi:
- 730 10.1371/journal.pcbi.1004219
- 45. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across
- 732 human tissues. Science. 2020;369:1318-1330. doi: 10.1126/science.aaz1776
- 46. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to
- variable selection in regression, with application to genetic fine mapping. *J R Stat*
- 735 Soc Series B Stat Methodol. 2020;82:1273-1300. doi: 10.1111/rssb.12388
- 736 47. Wallace C. A more accurate method for colocalisation analysis allowing for
- multiple causal variants. *PLoS Genet*. 2021;17:e1009440. doi:
- 738 10.1371/journal.pgen.1009440
- 48. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, Van
- Hout CV, Habegger L, Buckler D, Lai KM, et al. Inactivating Variants in

35

741	ANGPTL4 and Risk of Coronary A	rtery Disease.	. N Engl J Med. 2016;374:1123-
-----	--------------------------------	----------------	--------------------------------

- 742 1133. doi: 10.1056/NEJMoa1510926
- 49. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, Sirugo G,
- 744 Kember RL, Drivas TG, Dudek SM, et al. The Penn Medicine BioBank: Towards
- a Genomics-Enabled Learning Healthcare System to Accelerate Precision
- 746 Medicine in a Diverse Population. *J Pers Med.* 2022;12. doi:
- 747 10.3390/jpm12121974
- 50. Loh P-R, Danecek P, Palamara PF, Fuchsberger C, A Reshef Y, K Finucane H,
- 749 Schoenherr S, Forer L, McCarthy S, Abecasis GR, et al. Reference-based
- phasing using the Haplotype Reference Consortium panel. *Nature Genetics*.

751 2016;48:1443-1448. doi: 10.1038/ng.3679

- 51. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew
- 753 EY, Levy S, McGue M, et al. Next-generation genotype imputation service and
- 754 methods. *Nature Genetics*. 2016;48:1284-1287. doi: 10.1038/ng.3656
- 755 52. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D.
- 756 Principal components analysis corrects for stratification in genome-wide
- association studies. *Nature Genetics*. 2006;38:904-909. doi: 10.1038/ng1847
- 53. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins
- 759 RL, Laricchia KM, Ganna A, Birnbaum DP, et al. The mutational constraint
- spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581:434-
- 761 443. doi: 10.1038/s41586-020-2308-7
- 54. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S,
- 763 Musolf A, Li Q, Holzinger E, Karyadi D, et al. REVEL: An Ensemble Method for

764	Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet.
-----	---

- 765 2016;99:877-885. doi: 10.1016/j.ajhg.2016.08.016
- 55. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde
- 767 M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of
- sequence variants: a joint consensus recommendation of the American College
- of Medical Genetics and Genomics and the Association for Molecular Pathology.
- 770 *Genet Med.* 2015;17:405-424. doi: 10.1038/gim.2015.30
- 56. All of Us Research Program Genomics I. Genomic data in the All of Us Research
- 772 Program. *Nature*. 2024;627:340-346. doi: 10.1038/s41586-023-06957-x
- 57. Venner E, Patterson K, Kalra D, Wheeler MM, Chen YJ, Kalla SE, Yuan B,
- Karnes JH, Walker K, Smith JD, et al. The frequency of pathogenic variation in
- the All of Us cohort reveals ancestry-driven disparities. *Commun Biol.*
- 776 2024;7:174. doi: 10.1038/s42003-023-05708-y
- 58. Khan A, Turchin MC, Patki A, Srinivasasainagendra V, Shang N, Nadukuru R,
- Jones AC, Malolepsza E, Dikilitas O, Kullo IJ, et al. Genome-wide polygenic
- score to predict chronic kidney disease across ancestries. *Nat Med.*
- 780 2022;28:1412-1420. doi: 10.1038/s41591-022-01869-1
- 59. Marcot BG, Hanea AM. What is an optimal value of k in k-fold cross-validation in
- 782 discrete Bayesian network analysis? Computational Statistics. 2021;36:2009-
- 783 2031. doi: 10.1007/s00180-020-00999-9
- Kuhn MW, H. Tidymodels: a collection of packages for modeling and machine
 learning using tidyverse principles. 2020.

- 786 61. Wilimitis D, Walsh CG. Practical Considerations and Applied Examples of Cross-
- 787 Validation for Model Development and Evaluation in Health Care: Tutorial. JMIR
- 788 *Al.* 2023;2:e49023. doi: 10.2196/49023
- 789 62. Kruschke JK, Liddell TM. The Bayesian New Statistics: Hypothesis testing,
- restimation, meta-analysis, and power analysis from a Bayesian perspective.
- 791 Psychon Bull Rev. 2018;25:178-206. doi: 10.3758/s13423-016-1221-4
- 792 63. Kruschke JK. Rejecting or Accepting Parameter Values in Bayesian Estimation.
- 793 Advances in Methods and Practices in Psychological Science. 2018;1:270-280.
- 794 doi: 10.1177/2515245918771304
- Kuhn M. tidyposterior: Bayesian Analysis to Compare Models using Resampling
 Statistics. 2022.
- Harrell F. Statistically Efficient Ways to Quantify Added Predictive Value of New
 Measurements. In: *Statistical Thinking*. 2018.
- 799 66. Harrell JFE. Regression Modeling Strategies : With Applications to Linear
- 800 Models, Logistic and Ordinal Regression, and Survival Analysis. In: Springer
- 801 Series in Statistics, Cham: Springer International Publishing : Imprint: Springer,;
- 802 2015:1 online resource (XXV, 582 pages 157 illustrations, 553 illustrations in
- 803 color.
- 804 67. Fronczek J, Polok K, de Lange DW, Jung C, Beil M, Rhodes A, Fjølner J, Górka
- 805J, Andersen FH, Artigas A, et al. Relationship between the Clinical Frailty Scale
- and short-term mortality in patients $\supseteq B0$ years old acutely admitted to the ICU:
- 807 a prospective cohort study. *Critical Care*. 2021;25:231. doi: 10.1186/s13054-021-
- 808 03632-3

38

- 809 68. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or
- 810 more correlated receiver operating characteristic curves: a nonparametric
- 811 approach. *Biometrics*. 1988;44:837-845.
- 812 69. Akashi M, Higashi T, Masuda S, Komori T, Furuse M. A coronary artery disease-
- 813 associated gene product, JCAD/KIAA1462, is a novel component of endothelial
- cell-cell junctions. *Biochem Biophys Res Commun.* 2011;413:224-229. doi:
- 815 10.1016/j.bbrc.2011.08.073
- 816 70. Douglas G, Mehta V, Al Haj Zen A, Akoumianakis I, Goel A, Rashbrook VS,
- 817 Trelfa L, Donovan L, Drydale E, Chuaiphichai S, et al. A key role for the novel
- 818 coronary artery disease gene JCAD in atherosclerosis via shear stress
- 819 mechanotransduction. *Cardiovasc Res.* 2020;116:1863-1874. doi:
- 820 10.1093/cvr/cvz263
- 821 71. Guo B, Greenwood PL, Cafe LM, Zhou G, Zhang W, Dalrymple BP.
- 822 Transcriptome analysis of cattle muscle identifies potential markers for skeletal
- muscle growth rate and major cell types. *BMC Genomics*. 2015;16:177. doi:
- 824 10.1186/s12864-015-1403-x

39

826 **Tables, Figures, and Figure Legends**

827 Table 1: Clinical characteristics of Penn Medicine Biobank individuals with and

828 without thoracic aortic dissection.

Penn Medicine Biobank Participant Characteristics					
		Non-Dissection	Dissection		
Cohort Size, N		42987	262		
Sex					
	Female (%)	21576 (50%)	86 (33%)		
	Male (%)	21411 (50%)	176 (67%)		
Population					
	AFR (%)	11035 (26%)	76 (29%)		
	EUR (%)	29770 (69%)	177 (68%)		
	Other (%)	2182 (5.1%)	9 (3%)		
Age in years, median (IQR)		57.2 (42.5-67.2)	63.4 (53.9-71.1)		
Height in cm, median (IQR)		170.2 (162.6-177.8)	175.3 (166.8-182.9)		
Weight in kg, median (IQR)		83.0 (70.1-97.9)	86.2 (75.1-98.7)		
Body mass index, median (IQR)		28.2 (24.7-33.0)	28.5 (25.5-31.7)		
Body surface area in meters squared, median (IQR)		1.96 (1.78-2.13)	2.02 (1.84-2.20)		
Blood pressure					
	Systolic, median (IQR)	126.3 (117.9-134.8)	127.5 (120.6-135.3)		
	Diastolic, median (IQR)	74.0 (69.0-79.0)	70.7 (65.6-76.4)		
Heart rate, median (IQR)		77.2 (70.3-84.5)	73.9 (65.7-82.1)		

829



41

Figure 1: Genome-wide association study results. A) Manhattan plot of multi-trait genome-wide association study-by-subtraction results subtracting AscAoD and DesAoD from TAAD. Each point represents a genetic variant. Genome-wide significant (P<5x10⁻⁸) loci are represented by peaks of red points that associate with diameter-independent dissection. The X-axis represents genomic position by chromosome and the y-axis represents the strength of association by -log₁₀(P-value). B) Candidate genes, grouped by chromosome, were assigned to each genome-wide significant (P<5x10⁻⁸) locus in the diameter-independent "dissection" (red) and compared to the previously published TAAD GWAS (blue), ascending aortic diameter GWAS (purple), and descending aortic diameter GWAS (green) with previously unreported candidate genes denoted by stars. The size of each point corresponds to the strength of the association represented by - log₁₀(P-value).





Central Illustration: GWAS-by-subtraction, polygenic risk score creation, and association of different PRS with prevalent thoracic aortic dissection in the Penn Medicine Biobank. Analytic approach to the GWAS-by-subtraction of diameterindependent dissection followed by polygenic risk score creation and multivariable logistic regression analysis of the Dissection-PRS, TAAD-PRS, and AscAoD-PRS among all individuals in the PMBB to determine respective association with prevalent thoracic aortic dissection, adjusting for age, sex, and the first five genetic principal components. AscAoD-PRS = Ascending aortic diameter polygenic risk score; CI = confidence interval; OR = Odds ratio; sd = standard deviation; TAAD-PRS = thoracic aortic aneurysm and dissection polygenic risk score; Dissection-PRS = thoracic aortic dissection polygenic risk score.

Figure 3: Association of Dissection-PRS with prevalent dissection in multivariable logistic regression analysis adjusting for different clinical risk factors.

Multivariable logistic regression analysis of the effect of Dissection-PRS on prevalent dissection adjusting for clinical risk factors, measured AscAoD, or clinical risk factors and measured AscAoD. Each logistic regression analysis was also adjusted for age, sex, and the first five genetic principal components. AscAoD = Ascending aortic diameter measured by TTE or CT; CI = confidence interval; OR = Odds ratio; sd = standard deviation; Dissection-PRS = thoracic aortic dissection polygenic risk score.

Figure 4: Logistic regression model receiver operator characteristic curve (ROC) and area under the ROC curve to predict thoracic aortic dissection. (A) Receiver operator characteristic curves for each of the primary models including Age + Sex, Age + Sex + CRF, Age + Sex + CRF + Dissection-PRS, Age + Sex + CRF + AscAoD, and Age + Sex + CRF + AscAoD + Dissection-PRS. (B) Corresponding area under the ROC curves with error bars demonstrating 95% confidence intervals for models utilized among all individuals. AscAoD = ascending thoracic aortic diameter; AUROC = area under the receiver operator characteristic curve; CI = 95% confidence interval; CRF = Clinical Risk Factors; Dissection-PRS = thoracic aortic dissection polygenic risk score.